PRN® Pharmacal Names Pharma Industry Veteran Powell Director of Marketing & Sales

Patrick Powell, PRN Pharmacal Director of Marketing & Sales

Patrick Powell, PRN Pharmacal Director of Marketing & Sales

(Pensacola, Fla. – July 23, 2014) – Pegasus Laboratories, makers of PRN® Pharmacal branded products, has named Patrick Powell as PRN Pharmacal Director of Marketing & Sales. Powell will be responsible for planning and directing the marketing and sales of PRN Pharmacal-branded animal health products sold into the ethical veterinary market.

“We are pleased to have Patrick join the company. He is a natural leader with major brand experience and an extensive network in animal health sales and distribution. He will greatly contribute to the strategic direction and continued growth of PRN Pharmacal,” said Jeff Santosuosso, Vice President-General Manager.

“I am pleased to have this opportunity to join PRN Pharmacal as the company is poised for continued growth. The company is performing well, has great products and a great presence in the industry. I now look forward to contributing to this high performing company and making it even better,” said Powell.

Prior to joining PRN Pharmacal, Powell was Vice President of Sales for Putney Inc. where he developed and managed the sales team and sales programs. Prior to joining Putney, Powell was Director of Sales, East and an Upper Midwest Sales Manager for Bayer Animal Health. Before joining Bayer, Powell served as a Regional Sales Manager for Fort Dodge Animal Health, a division of Wyeth.

Powell initially began his animal health career with Solvay Animal Health. He earned his Bachelor Science in Agriculture Business from Northwest Missouri State University, Maryville, Missouri.

Pegasus Laboratories manufactures products which are distributed and marketed to the veterinary profession under the name PRN Pharmacal. Brand names include PROIN® for canine urinary incontinence and Collasate Silver® gel. To learn more about PRN Pharmacal products, visit or call 1-800-874-9764.


Comments are closed.